Anti Cd 20 Ocrevus denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Ocrevus as Non-Formulary — and Your Options

A non-formulary denial means ocrelizumab (Ocrevus) is not included in UnitedHealthcare's drug formulary for your specific plan, or is placed on a tier that requires additional authorization before coverage is triggered. For a high-cost infused MS therapy, this denial is common — but it is not the end of the road. Formulary-exception and medical-necessity appeals are a well-established mechanism for obtaining non-formulary coverage when a drug is medically necessary and no adequate formulary alternative exists.

## Your Federal Appeal Rights

• Formulary exception / internal appeal: Most plans governed by ACA or ERISA are required to maintain a formulary-exception process. You may request an exception by demonstrating that every formulary alternative is contraindicated, has caused or is likely to cause adverse effects, or is otherwise clinically inappropriate for you.
• Internal appeal timeline: File within the deadline on your denial notice (commonly 180 days under ERISA §503 or applicable state law).
• External review: Under ACA §2719, a denial of a formulary-exception request that involves medical-necessity judgment is subject to independent external review. The standard window is approximately four months from final adverse internal determination. Expedited review is available within 72 hours for urgent situations.
• Formulary exceptions for specialty drugs: Regulators and external reviewers have repeatedly held that plans must grant formulary exceptions when no covered alternative is clinically appropriate — particularly for specialty biologics with a distinct mechanism of action.

## Concrete Steps and Timeline

1. Obtain UHC's formulary for your specific plan year. Identify every MS disease-modifying therapy that is covered (formulary alternatives). 2. Review each formulary alternative with your neurologist. Document any clinical reason why each listed alternative is inadequate for your specific case. 3. Request UHC's formulary-exception / coverage-determination process. This is separate from (or the first step of) the standard appeal process. 4. File the formulary exception and internal appeal together with the documentation below. 5. If the exception and internal appeal are both denied, file for external review within the four-month window.

## Documentation to Gather

• Formulary alternative analysis: A letter from your neurologist addressing each formulary-listed DMT and explaining, for each, the specific clinical reason it is not appropriate for you (inadequate for your MS subtype, prior failure, intolerance, contraindication, or other reason). Reference the FDA-approved indications and applicable AAN or ECTRIMS guidelines.
• Diagnosis and MS subtype confirmation: Chart notes and MRI reports establishing your specific MS diagnosis. For primary progressive MS, note that the formulary alternatives approved for relapsing MS may not have an approved indication for PPMS — this is a strong basis for exception.
• Clinical severity: Disease activity and functional status documentation showing the clinical urgency of effective therapy.
• Prior treatment history: Dates, agents, and outcomes for all prior DMTs tried, particularly any formulary agents previously attempted.
• Prescriber medical-necessity letter: A detailed letter from your neurologist explaining why ocrelizumab specifically is medically necessary and no covered formulary agent is an adequate substitute.

## Criteria-Mapping Structure

Obtain the formulary-exception criteria from UHC's Exception Request form or coverage policy. Map each requirement:

| Exception Criterion | Your Evidence | |---|---| | Formulary alternative A is not appropriate | Neurologist letter: [clinical reason] | | Formulary alternative B is not appropriate | Neurologist letter: [clinical reason] | | Requested drug is medically necessary | Neurologist medical-necessity letter, diagnosis notes | | MS subtype matches approved indication | ICD-10 code, neurologist diagnosis note |

For primary progressive MS in particular, the absence of any formulary-listed agent with an FDA-approved PPMS indication is often dispositive in a formulary-exception appeal.